Topical cannabinoid enhances topical morphine antinociception

Pain

Volumn 105, Issue 1-2, 2003, Pages 303-308

  Yesilyurt, Ozgur ^a   Dogrul, Ahmet ^a   Gul, Husamettin ^a   Seyrek, Melik ^a   Kusmez, Ozkan ^a   Ozkan, Yalcin ^a   Yildiz, Oguzhan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Analgesia; Antinociception; Cannabinoid; CB1 receptor; Morphine; Opioid; WIN 55, 212 2

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; DIMETHYL SULFOXIDE; MORPHINE; OPIATE AGONIST; UNCLASSIFIED DRUG;

ANTINOCICEPTION; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; MALE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; TAIL FLICK TEST;

EID: 0141626772     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(03)00245-8     Document Type: Article

References (34)

1. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 100:2000;685-688.
2. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 58:1999;315-348.
3. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
4. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann N Y Acad Sci. 654:1992;33-51.
5. Cichewicz D.L., Martin Z.L., Smith F.L., Welch S.P. Enhancement mu opioid antinociception by oral delta 9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther. 289:1999;859-867.
6. Cichewicz D.L., McCarthy E.A. Antinociceptive synergy between Delta 9-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 304:2003;1010-1015.
7. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hypocampal neurons. Receptors Channels. 1:1993;121-134.
8. Dogrul A, Gul H, Akar A, Yildiz O, Bilgin F, Guzeldemir E. Topical cannabinoid analgesia: synergy with spinal sites. Pain 2003;105:11-6.
9. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral Cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
10. Gatley S.J., Gifford A.N., Volkov N.D., Lan R., Makriyannis A. I-labeled AM 251: radioiodinated ligand which binds in vivo to mouse brain cannabinoid receptors. Eur J Pharmacol. 307:1996;331-338.
11. Ghozland S., Matthes H.W., Simonin F., Filliol D., Kieffer B.L., Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci. 22:2002;1146-1154.
12. Hohmann A.G., Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett. 252:1998;13-16.
13. Hohmann A.G., Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1999;1171-1175.
14. Hylden J.L.K., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 67:1980;313-316.
15. Hymson D.L., Hynes M.D. Evidence that ethanol-induced impairment of roto-rod performance is not mediated by opioid mechanisms. Prog Neuropsychopharmacol Biol Psychiatry. 6:1982;159-165.
16. Kolesnikov Y.A., Jain S., Wilson R., Pasternak G.W. Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. J Pharmacol Exp Ther. 79:1996;502-506.
17. Kolesnikov Y.A., Pasternak G.W. Topical opioid in mice: analgesia and reversal of tolerance by a topical N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 290:1999;247-252.
18. Kolesnikov Y.A., Pasternak G.W. Peripheral blockade of topical morphine tolerance by ketamine. Eur J Pharmacol. 374:1999;R1-R2.
19. Kolesnikov Y.A., Chereshnev I., Pasternak G.W. Analgesic synergy between topical lidocaine and topical opioids. J Pharmacol Exp Ther. 295:2000;546-551.
20. Laduron P.M. Axonal transport of opiate receptors in capsaicin sensitive neurons. Brain Res. 294:1984;157-160.
21. Massi P., Vaccani A., Romorini S., Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol. 117:2001;116-124.
22. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 383:1996;819-823.
23. Ono T., Inoue M., Rashid M.H., Sumikawa K., Ueda H. Stimulation of peripheral nociceptor endings by low dose morphine and its signaling mechanism. Neurochem Int. 41:2002;399-407.
24. Pugh G. Jr, Welch S.P., Bass P.P. Modulation of free intracellular calcium and cAMP by morphine and cannabinoids, alone and in combination in mouse brain and spinal cord synaptosomes. Pharmacol Biochem Behav. 49:1994;1093-1100.
25. Pugh G., Smith P.B., Dombrowski D.S., Welch S.P. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther. 279:1996;608-616.
26. Pugh G., Mason D.J., Combs V., Welch S.P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther. 281:1997;730-737.
27. Salio C., Fischer J., Franzoni M.F., Mackie K., Kaneko T., Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. NeuroReport. 12:2001;3689-3692.
28. Shaaban A.M., Zhang Q., Nicolle S., Ru-Rong J., Stein C. B-Endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. J Neuroimmunol. 115:2001;71-78.
29. Shapira M., Vogel Z., Sarne Y. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell Mol Neurobiol. 20:2000;291-304.
30. Smith F.L., Cichewitcz D., Martin Z.L., Welch S.P. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol Biochem Behav. 60:1998;559-566.
31. Stander S., Gunzer M., Metze D., Luger T., Steinhoff M. Localization of mu-opioid receptor 1 A on sensory nerve fibers in human skin. Regul Pept. 110:2002;75-83.
32. Welch S.P., Eads M. Synergistic interaction of endogenous opioids and cannabinoid systems. Brain Res. 848:1999;183-190.
33. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther. 262:1992;10-18.
34. Welch S.P., Thomas C., Patric G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanism for interaction with morphine. J Pharmacol Exp Ther. 272:1995;310-321.